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Running header 
Impact of depression on HIV outcomes 
 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, 
share, remix, transform, and buildup the work provided it is properly cited. The work cannot 
be used commercially without permission from the journal 
 
Abstract  
Background: There is still wide variability in HIV disease course and other HIV related 
outcomes, attributable in part to psychosocial factors such as major depressive disorder 
(MDD), a subject that has received little attention in sub-Saharan Africa. 
Methods: Using a longitudinal cohort of 1099 HIV positive antiretroviral therapy (ART) 
naïve persons, we investigated the impact of MDD on four HIV related negative outcome 
domains in Uganda. MDD was assessed using a Diagnostic Statistical Manual IV based tool. 
Also collected was data on surrogate measures of the HIV related outcome domains.  Data 
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was collected at the three time points of baseline, 6 and 12 months. Multiple regression and 
discrete time survival models were used to investigate the relationship between MDD and 
indices of the HIV outcomes.     
Results: MDD was a significant predictor of ‘missed ART doses’ (aOR=4.75, 95% CI, 1.87-
12.04, p=0.001), ‘time to first visit to healthy facility’ (aOR=1.71; 95% CI, 1.07-2.73; 
p=0.024),  ‘time to first self-reported risky sexual activity’ (aOR=2.11, 95% CI, 1.27-3.49; 
p=0.004) but not of  ‘CD4 counts at months 6 and 12’ (estimated effect 29.0; 95% CI, -7.8-
65.7; p=0.12) and ‘time to new WHO stage 3 or 4 clinical event’ (aOR=0.52, 95% CI, 0.12-
2.20, p=0.37). 
Conclusion: MDD significantly impacted three of the four investigated outcome domains. 
These results by demonstrating the adverse consequences of an untreated mental health 
disorder (MDD) on HIV related outcomes, further strengthen the need to urgently act on 
WHO’s call to integrate mental health care in general HIV care.  
Key Words: Major depressive disorder, HIV outcome measures, ART adherence, risky 
sexual behaviour, HIV disease progression, health seeking behaviour, Africa     
Background 
Depressive disorders are estimated to account for 40% of the 183·9 million disability-
adjusted life years (DALYs) lost worldwide due to mental and substance use disorders with 
more than 80% of this non-fatal disease burden occurring in low- and middle-income 
countries.1 HIV/AIDS is one of the physical disorders associated with depressive disorders 
with rates of between 8 to 30% reported in   sub-Saharan African studies.2 Major depressive 
disorder (MDD) in HIV not only leads to severe psychological distress, it has been implicated 
in the still wide variability observed in HIV disease course and other related clinical and 
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behavioural outcomes. In studies largely carried out in the west, MDD has been associated 
with faster HIV disease progression,3-5 poor drug adherence,6-7 poor health seeking 
behaviour8 and risky sexual behaviour.9 Cross-sectional investigation of these associations is 
often complicated by the bidirectional causal relationships, hence the need for longitudinal 
study designs.10 To-date, only two such longitudinal studies have been undertaken in sub-
Saharan Africa, with one study showing that MDD negatively impacted HIV disease 
progression and mortality11 and the other study showing that MDD negatively impacted risky 
sexual behaviour.12 
Additionally, understanding the relationship between MDD and HIV related outcomes in a 
given socio-cultural context has implications for the design of HIV related clinical trials and 
for programmatic development in HIV care. On clinical trial design, studies in this area will 
inform which HIV related outcomes could be used as secondary outcome measures in trials 
that target depression in HIV in a given socio-cultural context. At the programmatic level, 
such studies will inform which psychosocial factors in a given socio-cultural context should 
additionally be targeted to attain maximum impact against a given set of negative HIV related 
outcomes. In this study, we investigate the impact of MDD on indices of the four HIV related 
outcomes of HIV disease progression, adherence to HIV medications, health seeking 
behaviour and risky sexual behaviour using a longitudinal study design in Uganda. 
METHODS  
Study design and Site 
This was a prospective cohort study conducted in adult antiretroviral therapy (ART) naïve 
persons living with HIV (PLWH) attending at two specialised HIV clinics run by The AIDS 
Support Organisation (TASO) in Uganda.13 Data collection was undertaken at three time 
points: baseline (when participants undertook their first study interview after enrolment into 
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the study) 6-months after the baseline assessment and 12-months after baseline assessment. 
Initiation of ART was implemented by TASO independently of the study.  
At the time of the study, national treatment guidelines for HIV-infected individuals 
recommended the initiation of ART at a CD4 cell count of below 250 cells / µl. In addition, 
individuals initiating ART were required to have identified an appropriate treatment 
supporter.  
Sampling Procedure 
The TASO clinic in Entebbe (semi-urban site) has 7,000 active clients of whom about 3,000 
are ART naïve while the TASO clinic at Masaka (predominantly rural site)  has  6,000 active 
clients of whom about 2,500 are not on ART. This study aimed to enrol 1100 ART naïve 
HIV-infected adults from the two clinics. This sample size was chosen to ensure that the 
baseline prevalence of MDD would be estimated with sufficient precision and would also be 
sufficient to detect moderate associations between MDD and HIV clinical and behavioural 
outcomes. To obtain the required sample from the two HIV clinics, a sub-register of all active 
clients who were not on ART was created. From these sub-registers a random sample of ART 
naïve patients was recruited from each study clinic using a table of random numbers until a 
combined total study sample of 1100 was obtained. About 2% of selected patients could not 
be recruited into this study because of any one of the following reasons: i) they did not meet 
eligibility criteria; nor ii) were already enrolled in another study nor iii) refused to participate 
in the study for any other reason.  
The inclusion criteria for this study were: i) a person living with HIV/AIDS who was ART 
naïve and registered with the outpatient clinic at either TASO Entebbe and TASO Masaka 
clinics; ii) aged at least 18 years old at enrolment; iii) conversant in Luganda, the language in 
which the study instruments were translated.  Exclusion criteria were patients who were too 
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sick or unable to understand the study instruments, and those who had missed their most 
recent scheduled clinic visit.  Eligible participants were recruited after they had provided 
written informed consent after explanation of the study objectives and procedures.   
Data collection tools 
The data collection tools consisted of structured and standardised locally translated 
psychosocial assessment instruments, most of which have previously been used among 
persons living with HIV (PLWH) in Uganda by this study group.14 Study  variables from 
these instruments were categorised as follows: socio-demographic factors: these included 
study site, sex, age, highest educational attainment, marital status, religion, occupation and 
socio-economic index (SES index) constructed from commonly available household items in 
a typical Ugandan households and previously used by this research group;14 Exposure 
variable: Current major depressive disorder (MDD) which is the exposure in this study was 
assessed using the Diagnostic Statistical Manual IV based MDD module of the Mini 
International Neuropsychiatric Interview (M.I.N.I.-Plus),  a tool though never formerly 
validated in Uganda but has been subject to a formal translation process and used quite 
extensively.15 MDD was assessed at each of the three time points of baseline, 6 months and at 
12 months. MDD was reported as a binary outcome with respondents reported as either 
having MDD or not having MDD. A diagnosis of current MDD was made if the respondent 
within a time period of not less than two weeks, met the following three symptom criteria: i) 
Criteria 1: must have at least one of the two symptoms (i) or (ii):  i) feeling depressed or 
down, most of the day, nearly every day; ii) had lost interest in most things or much less able 
to enjoy the things they used to enjoy most of the time; Criteria 2: must have a total of at least 
five symptoms from the list of (i) to (ix), symptoms (i) and (ii) are described under criteria 1,  
while symptoms (iii) to (ix) are now described: iii) experienced weight increase or decrease 
without trying intentionally; iv) had trouble sleeping nearly every night; v) talked or moved 
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more slowly than normal or were having trouble sitting still almost every day; vi) feeling 
tired or without energy almost every day; vii) feeling worthless or guilty almost every day; 
viii) had  difficulty concentrating or making decisions almost every day; ix) repeatedly 
considered hurting yourself, feeling suicidal, or wishing that you were dead, or attempted 
suicide or had a suicide plan; Criteria 3: the above listed symptoms should cause significant 
problems at home, at work, socially, or at school or in some other important way. 
 Indices of HIV related outcome measures: data on these indices was collected at each of the 
three data collection time points of baseline, 6 months and 12 months. These indices were 
grouped into the following four domains, i) HIV disease progression (CD4 counts, WHO 
Clinical Staging criteria16); ii) health seeking behaviour (number of visits to health facilities 
in last month14); iii) adherence to HIV medications (three day antiretroviral therapy pill count 
recall14); and iv) risky sexual behaviour (assessed by inquiring about five risky sexual 
behaviours that have been associated with HIV transmission in the Ugandan cultural 
context,17 these questions were, ‘In the last month, have you: i) had sex with anyone other 
than your regular partner?; ii) have you had sex in exchange for gifts/money?; iii) have you 
had forced sex including rape?; iv) have you had sex with someone much older/younger than 
you?; v) have you had sex with someone you had just met?)’. 
Statistical Analysis 
The impact of MDD on the four HIV-related outcome domains was investigated using five 
outcome variables, as described below: 
HIV disease progression domain 
i) CD4 count at visit 2 (6 months) and visit 3 (12 months) was one of the outcome variables 
used to measure the domain HIV disease progression. The analysis used a “long” data set 
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which included for each participant the CD4 cell count at month 6 and month 12. The 
primary exposure, MDD, was lagged i.e. MDD at baseline was used as the exposure variable 
for CD4 count at month 6, while MDD at month 6 was used as the exposure for CD4 count at 
month 12. The reason for lagging MDD was that the CD4 count at a particular visit was 
deemed to reflect everything that happened in the previous 6 month period. Multiple linear 
regression models were fitted with the use of robust standard errors to account for the 
correlation between CD4 counts within participants. It was felt that two observations per 
subject was too few to fit linear mixed models for repeated measurements. The analysis 
adjusted for study site, sex, age, visit (i.e. month 6 or month 12) and baseline CD4 cell count 
as explanatory variables. Participants who initiated ART between baseline and month 6 were 
excluded, while participants who initiated ART between month 6 and month12 were included 
at month 6 but excluded at month 12. The measure of effect for CD4 count is the difference 
in CD4 cell count (cells / µl) between participants with MDD (at the previous visit) and those 
without MDD. 
ii) Having experienced a WHO stage 3 or 4 event at month 6 or month 12 was also used to 
measure the domain HIV disease progression. The time to the first WHO stage 3 or 4 event 
was analysed using discrete time survival models.18-19 Discrete-time survival models were 
used to investigate the time (6 months or 12 months) to the first WHO stage 3 or 4 event. In 
practice this is done by fitting logistic regression models, so although the derivation is based 
on the hazard (risk of an event at the given visit), the parameters of the model can be 
interpreted as odds ratios. The primary exposure, MDD, was lagged i.e. MDD at baseline was 
used as the exposure variable for a WHO stage 3 or 4 event at month 6, while MDD at month 
6 was used as the exposure for a WHO stage 3 or 4 event at month 12. The analysis adjusted 
for study site, sex, age, visit (i.e. month 6 or month 12) and baseline CD4 cell count as 
explanatory variables.  
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Participants who initiated ART before month 6 were excluded, while those who initiated 
ART between month 6 and month 12 were included at month 6 but excluded at month 12. 
Participants who had already experienced a WHO stage 3 or 4 event at baseline were also 
excluded from the analysis. The measure of effect is the (adjusted) odds ratio for a WHO 
stage 3 or 4 event for participants with MDD (at the previous visit) compared to those 
without MDD. 
 
Adherence to HIV medications domain 
iii) Having missed at least one dose of ART medications in the three days prior to the 
interview was used as a measure for the domain on adherence to HIV medication. Missing at 
least one dose of ART at month 6 and month 12 was analysed by fitting a multiple logistic 
regression model to a “long” data set with up to 2 observations per participant; robust 
standard errors were used to account for the correlation of responses within participants.  In 
this case the primary exposure (MDD) was not lagged, since the MDD was evaluated over 
the two weeks prior to the visit and missing at least one dose of ART was evaluated over the 
three days prior to the visit, so we assumed that the exposure (MDD) preceded the outcome 
(missing at least one dose of ART). The analysis adjusted for study site, sex, age, visit (i.e. 
month 6 or month 12) and baseline CD4 cell count as explanatory variables. The analysis was 
restricted to participants who initiated ART between baseline and month 6 (who were 
included at month 6 and month 12) and participants who initiated ART between month 6 and 
month 12 (who were included at month 12 only). The measure of effect is the (adjusted) odds 
ratio for missing at least one dose of ART for participants with MDD compared to those 
without MDD. 
Health seeking behaviour domain  
AC
CE
PT
ED
Copyright © 2018  The Author(s). Published by Wolters Kluwer Health, Inc. 
10 
 
(iv) The time to the first visit to a health facility was used as a measure of health seeking 
behaviour and was analysed using discrete time survival models. The primary exposure, 
MDD, was lagged i.e. MDD at baseline was used as the exposure variable for a visit to a 
health facility at month 6, while MDD at month 6 was used as the exposure variable for a 
visit to a health facility at month 12. The analysis adjusted for study site, sex, age, visit (i.e. 
month 6 or month 12) and baseline CD4 cell count as explanatory variables. Participants who 
had their first visit to a health facility at baseline were excluded from the analysis, while 
those who visited a health facility between month 6 and month 12 were included at month 6 
but excluded at month 12. The measure of effect is the (adjusted) odds ratio for a visit to a 
health facility for participants with MDD (at the previous visit) compared to those without 
MDD. 
Risky sexual behaviour domain  
v) Having engaged in risky sexual behaviour (as measured by at least one affirmative answer 
to the five questions on sexual behaviour) was analysed using discrete time survival models. 
The primary exposure (MDD) was lagged. The analysis adjusted for study site, sex, age, visit 
and baseline CD4 count as explanatory variables. Participants who had engaged in risky 
sexual behaviour at baseline were excluded from the analysis, while those who engaged in 
risky sexual behaviour at month 6 were excluded  at month 12. The measure of effect is the 
(adjusted) odds ratio for risky sexual behaviour for participants with MDD (at the previous 
visit) compared to those without MDD. 
We did not adjust for multiple significance testing. While this increases the chance of type I 
errors, the aim of the analysis was to identify potentially detrimental consequences of MDD 
which can be seen as analogous to safety analysis in drug trials in which the aim is to identify 
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potential risks caused by the investigational drug, in which case adjusting for multiplicity is 
not recommended.20  
    
Ethical Considerations 
The study obtained ethical approval from the Uganda Virus Research Institute’s Science and 
Ethics Committee and the Uganda National Council of Science and Technology.  Study 
participants were invited to consent and participate in this study by trained psychiatric nurses 
after being provided with adequate information about the study. Respondents found to have 
significant psychiatric problems were referred to psychiatric departments nearest to their 
study sites for further assessment and management. 
 
RESULTS  
Overall retention in the study at one year was high, with 1,041 (94.7%) of participants seen at 
month 12. Of the 1099 participants assessed at baseline, 67 (6.2%) were lost to follow-up by 
12 months, of whom 18 were confirmed to have died during the course of this study, the 
majority due to non HIV related causes. None of the factors of study site, sex, marital status 
and baseline MDD were associated with loss to follow-up. In this study, missing data of not 
more than 1% was recorded on the variables educational status, marital status, current MDD, 
visits to health facilities in the past month and any risky sexual activity. It was only on the 
variable WHO stage that missing data of 2.8% was recorded at the 12 months data collection 
time point (see Table 1 for details).  
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Socio-demographic factors, psychosocial exposure and HIV related outcomes   
                                                        insert Table 1 
A summary of socio-demographic data, psychosocial exposure variable and clinical and 
behavioural outcomes are given in Table 1.  A detailed description of the characteristics of 
this study population can be found in earlier publications.2, 21 The number of participants at 
the two study sites was similar throughout the three reporting periods (baseline, 6 months and 
12 months).  Overall just over three-quarter of participants were female and the mean age 
overall was 35 years. Only 296 (27%) of participants had secondary or higher education. 
About half of the participants were currently married, with less than 104 (10%) having never 
been married. The proportion of respondents with a current episode of major depressive 
disorder (MDD) decreased from 155 (14%) at baseline to 59 (5.6%) at month 6 and to a 
further 44 (4.2%) at month 12.   
 
In this study, CD4 cell counts showed large variability, both between participants and 
between periods within participants. The CD4 count increased over time; this increase can be 
partly explained by the fact that participants who started ART, and who had the lowest CD4 
counts, were excluded from the subsequent analysis of CD4 counts. The baseline CD4 counts 
were based on 1099 participants, while at month 6 the CD4 counts were based on 694 
participants who had not yet started ART and at month 12 the CD4 counts were based on 547 
participants who had not yet started ART. Few participants experienced a new WHO stage 3 
or 4 event, 6% at baseline, of those without a baseline event, 3.4% at month 6 and of the 
remainder 4.6% at month 12. 
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Associations between the MDD and HIV clinical and behavioural outcomes 
Given below are the results of fitting models to find associations between MDD and HIV 
related clinical and behavioural outcomes. 
                                                                   insert  Table 2 
Model for CD4 counts 
The analysis of the CD4 count by fitting a linear regression model, with the use of robust 
variance estimation to adjust for the within-subject correlation at month 6 and month 12, was 
based on 694 participants at month 6 and 547 participants at month 12; participants were 
excluded from this analysis if they had initiated ART prior to the visit concerned. The results 
of fitting the linear regression model with robust variance estimators are summarised in Table 
2a. MDD was not significantly associated with the CD4 count at the follow-up visits, 
adjusting for study site, sex, age and baseline CD4 count. The estimated effect showed that 
participants with MDD had higher CD4 counts on average, but the difference was not 
statistically significant (estimated effect 29.0; 95% CI,     -7.8-65.7; p=0.12).  
 
Model for time to first new WHO stage 3 or 4 event  
The analysis of the time to the first new WHO stage 3 or 4 event using a discrete time 
survival model was based on 706 participants, with 333 participants excluded due to initiating 
ART and 28 participants excluded as they had experienced a WHO stage 3 or 4 event at 
baseline. In total 24 participants experienced a WHO stage 3 or 4 event at month 6 and a 
further 25 participants experienced a WHO stage 3 or 4 event at month 12. The results of 
fitting the discrete time survival model are summarised in Table 2b. MDD was not 
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significantly associated with the odds of experiencing a WHO stage 3 or 4 event, adjusting 
for study site, sex, age and baseline CD4 count (aOR =0.52; 95% CI, 0.12-2.20; p=0.37). 
Model for having missed a dose of ART 
The analysis of having missed at least one dose of ART was based on 468 participants of 
whom 333 had initiated ART by month 6. At month 6, 30/333 participants missed at least one 
dose of ART in the 3 days prior to the visit, while at month 12, 31/468 participants missed at 
least one dose of ART. The results of fitting a logistic regression model with robust variance 
estimators are summarised in Table 2c. Adjusting for study site, sex, age and baseline CD4 
count, the odds of having missed at least one dose of ART were 4.75 times as high for 
participants with MDD compared to those without MDD (aOR=4.75; 95% CI, 1.87-12.04); 
p=0.001). 
 
Model for having visited a health facility 
The analysis of the time to the first visit to a health facility using a discrete time survival 
model was based on 763 participants; the 309 participants who had visited a health facility at 
baseline were excluded from the analysis. In total 146 participants visited a health facility in 
the month before visit 2 (month 6) and a further 77 participants visited a health facility in the 
month before visit 3 (month 12). The results of fitting a discrete time survival model are 
summarised in Table 2d. Adjusting for study site, sex, age and baseline CD4 count, the odds 
of having undertaken a visit to the health facility were 1.71 times as high for participants with 
MDD (at the previous visit) compared to those without MDD (aOR=1.71; 95% CI, 1.07-2.73; 
p=0.024). 
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Model for any risky sexual behaviour 
The analysis of the time to the first self-reported risky sexual behaviour using a discrete time 
survival model was based on 906 participants; 147 participants were excluded as they 
reported having engaged in risky sexual behaviour at baseline, while 20 participants had 
missing responses to all five questions at month 6 and 36 participants had missing responses 
to all five questions at month 12. In total 74 participants reported in having engaged in risky 
sexual behaviour at month 6 and a further 67 reported having engaged in risky sexual 
behaviour at month 12. The results of fitting a discrete time survival model are summarised in 
Table 2e. Adjusting for study site, sex, age and baseline CD4 count, the odds of having 
engaged in risky sexual behaviour were 2.11 times as high for participants with MDD (at the 
previous visit) compared to those without MDD (aOR=2.11; 95% CI, 1.27-3.49; P=0.004). 
DISCUSSION 
This to our knowledge is only the third paper from sub-Saharan Africa that has investigated 
the association between MDD and HIV related negative outcomes using a prospective study 
design to control for possible bidirectionality.10 While each of the two earlier studies only 
looked at the relationship between MDD and one HIV related outcome,11-12   this study 
investigated the relationship between MDD and indices of the four HIV related outcome 
domains of HIV disease progression, adherence to HIV medications, health seeking 
behaviour and risky sexual behaviour.   
Two indices were used to assess HIV disease progression in this study, namely, CD4 counts 
at 6 and 12 months and time to the first new WHO stage 3 or 4 event.  In this study we found 
no evidence that MDD at the previous visit was associated with either of these two indices 
used to assess for HIV disease progression. In the literature there are conflicting results on the 
association between MDD and HIV disease progression with some systematic reviews and 
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meta-analyses reporting a significant association4 while others do not report such a finding.22 
Possible explanations for these conflicting results include the complexity of the relationship 
between neuropsychiatric disorders such as MDD and the immune system in HIV/AIDS23-24 
and methodological issues including differences in study design and choice of HIV disease 
progression indicators4 and the high variability of some indices used as a surrogate measure 
of HIV disease progression.24  Indeed, the relationship between MDD and CD4 counts in this 
study could have been confounded by the wide variability shown by CD4 counts both 
between subjects and between time periods within subjects.   
 
In this study we found that MDD at the current visit was associated with nearly a five-fold 
increase in the odds of missing at least one dose of ART in the previous three days. While we 
feel this was a fairly robust finding, it is important to note that there were smaller numbers on 
ART compared to the cohort as a whole. In line with these findings, two previous systematic 
reviews have reported that depression negatively impacted ART adherence.6,25 On health 
seeking behaviour, our findings were that having a previous episode of MDD was associated 
with a nearly two-fold increased risk of visiting a health facility. While previous studies have 
reported MDD as a predictor of poor access to general HIV care services,8 a multi-site 
European study reported increased utilisation of psychiatric services by individuals with 
MDD in the community.26 The increased utilisation of HIV care services that was associated 
MDD in this study may have been a ‘cry for help’ from persons experiencing psychological 
distress whose needs were not being met by an HIV care system that is not yet responsive to 
the mental health needs of persons living with HIV. We did not control for distance between 
the respondent’s home and the HIV clinic, a variable that could have confounded the above 
relationship.  
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We observed that MDD was associated with a two-fold increased risk of engaging in risky 
sexual behaviour. Both Seth and colleagues (2011)9 among female African American 
adolescents in the United States of America and Nduna and colleagues (2010)12 among young 
adults in South Africa have reported MDD as a significant predictor of risky sexual 
behaviour.  
In conclusion, this study has demonstrated that MDD significantly impacted the HIV related 
outcome domains of adherence to HIV medications, health seeking behaviour and risky 
sexual behaviour but not of HIV disease progression. These results add further weight to the 
recent recommendation by the WHO to integrate mental health into HIV care services27 by 
demonstrating the adverse consequences of an untreated mental health disorder (MDD) on 
HIV related clinical and behavioural outcomes. Additionally, these results support an 
observation made by Collins et al (2006) who in a systematic review on the relevance of 
mental health to HIV/AIDS care and treatment programs in developing countries noted that 
behavioural factors including mental health disorders are likely to be a major determinant in 
ART roll.28 In response to this observation, Collins et al (2006) then called for 
methodologically sound studies,  such as this one, that among others describe the mental 
health-related predictors of ART adherence. Finally, these results suggest that in the sub-
Saharan African setting of Uganda, psychosocial factors such as MDD should among others 
be targeted in the design of interventions to address the HIV outcomes of adherence to HIV 
medications, health seeking behaviour and risky sexual behaviour. There is however need for 
more studies to further validate these findings in this socio-cultural context.  
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Table 1: Socio-demographics, psychosocial exposures and HIV related outcomes of the  
               study population by data collection time period  
Factor Level Baseline Month 6 Month 12 
Overall  1099 1059 1041 
Socio-demographics    
Study Site Entebbe 
Masaka 
542 (49.3%) 
557 (50.7%) 
520 (49.1%) 
539 (50.9%) 
509 (48.9%) 
532 (51.1%) 
Sex Male 
Female 
252 (22.9%) 
847 (77.1%) 
243 (23.0%) 
816 (77.0%) 
238 (22.9%) 
803 (77.1%) 
Age Mean (s.d.) 
Median (IQR) 
35.1 (9.3) 
34 (28 – 41) 
35.1 (9.3) 
34 (28 – 41) 
35.1 (9.1) 
34 (28 – 41) 
Age (grouped) 18 – 29  
30 – 34 
35 – 39 
40 – 49 
>=50 
339 (30.8%) 
252 (22.9%) 
197 (17.9%) 
225 (20.5%) 
86 (7.8%) 
321 (30.3%) 
248 (23.4%) 
188 (17.8%) 
218 (20.6%) 
84 (7.9%) 
316 (30.4%) 
244 (23.4%) 
185 (17.8%) 
216 (20.8%) 
80 (7.7%) 
Education Status None 
Primary  
Secondary or more 
Missing 
120 (10.9%) 
680 (61.9%) 
296 (26.9%) 
3 (0.3%) 
113 (10.7%) 
654 (61.8%) 
289 (27.3%) 
3 (0.3%) 
113 (10.8%) 
641 (61.6%) 
284 (27.3%) 
3 (0.3%) 
Marital Status Currently married 
Widowed 
Separated / divorced 
Single 
Missing 
563 (51.2%) 
163 (14.8%) 
267 (24.3%) 
104 (9.5%) 
2 (0.2%) 
540 (51.0%) 
157 (14.8%) 
261 (24.6%) 
99 (9.4%) 
2 (0.2%) 
533 (51.2%) 
158 (15.2%) 
254 (24.4%) 
94 (9.0%) 
2 (0.2%) 
Religion Catholic 
Protestant 
Muslim 
Seventh Day  
Born Again 
Other 
586 (53.3%) 
237 (21.6%) 
163 (14.8%) 
16 (1.5%) 
93 (8.5%) 
4 (0.4%) 
566 (53.4%) 
228 (21.5%) 
158 (14.9%) 
16 (1.5%) 
87 (8.2%) 
4 (0.4%) 
562 (54.0%) 
224 (21.5%) 
152 (14.6%) 
14 (1.3%) 
85 (8.2%) 
4 (0.4%) 
Occupation Farmer / Fishing 
Professional / clerical 
Trader / Artisan / transport 
Unemployed / Retired / 
housewife 
Student / other 
324 (29.5%) 
43 (3.9%) 
396 (36.0%) 
139 (12.6%) 
187 (17.0%) 
10 (0.9%) 
321 (30.3%) 
42 (4.0%) 
386 (36.4%) 
126 (11.9%) 
174 (16.4%) 
10 (0.9%) 
310 (29.8%) 
42 (4.0%) 
383 (36.8%) 
126 (12.1%) 
172 (16.5%) 
8 (0.8%) 
SES index Mean (s.d.) 
Median (IQR) 
15.1 (3.6) 
15 (13 – 17) 
15.1 (3.6) 
15 (13 – 17) 
15.1 (3.6) 
15 (13 – 17) 
Psychosocial exposures    
Current MDD  No 
Yes 
Missing 
944 (85.9%) 
155 (14.1%) 
0 
991 (93.6%) 
59 (5.6%) 
9 (0.8%) 
987 (94.8%) 
44 (4.2%) 
10 (1.0%) 
HIV related outcomes    
CD4 count Mean (s.d.) 
Median (IQR) 
Geometric mean (95% C.I.) 
516.2 (267.6) 
471 (352 ; 665) 
430.7 (412 ; 450) 
560.6 (235.4) 
517 (407 ; 687) 
514.6 (498 ; 532) 
600.6 (233.4) 
556 (435 ; 711) 
516.1 (497 ; 537) 
WHO stage I 
II 
III / IV 
533 (48.5%) 
500 (45.5%) 
66 (6.0%) 
308 (45.4%) 
347 (51.2%) 
23 (3.4%) 
233 (43.3%) 
265 (49.3%) 
25 (4.6%) 
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Missing 0 0 15 (2.8%) 
Missed a dose of 
ART in past three 
days 
No 
Yes 
N/A 
 289 (86.8%) 
30 (9.0%) 
14 (4.2%) 
390 (83.3%) 
31 (6.6%) 
47 (10.0%) 
Visits to health 
facility in past 
month 
None 
Once 
Twice 
Three or more 
Missing 
781 (71.1%) 
146 (13.3%) 
85 (7.7%) 
86 (7.8%) 
1 (0.1%) 
603 (80.1%) 
70 (9.3%) 
45 (6.0%) 
31 (4.1%) 
4 (0.5%) 
507 (86.7%) 
47 (8.0%) 
18 (3.1%) 
10 (1.7%) 
3 (0.5%) 
Any Risky sexual 
activity 
No 
Yes 
Missing 
 950 (86.4%) 
149 (13.6%) 
0 
832 (91.0%) 
74 (8.1%) 
8 (0.9%) 
737 (90.9%) 
66 (8.1%) 
8 (1.0%) 
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Table 2: Results of fitting models to outcomes associated with MDD 
 
Table 2 a) Multiple linear regression with robust variance estimation for CD4 counts 
 
Factor Level Effect (Robust 95% c.i.) P-value 
Study SIte Entebbe 
Masaka 
0 (Reference) 
53.8 (28.3 ; 79.4) 
<0.001 
Sex Male 
Female 
0 (Reference) 
33.8 (4.5 ; 63.1) 
0.024 
Age Per 10 year increase -9.5 (-23.0 ; 4.1) 0.17 
Visit Visit 2 (Month 6) 
Visit 3 (Month 12) 
0 (Reference) 
23.6 (6.4 ; 40.9) 
<0.001 
Baseline CD4 count Per unit increase 0.56 (0.49 ; 0.63) <0.001 
MDD (lagged) No 
Yes 
0 (Reference) 
29.0 (-7.8 ; 65.7) 
0.12 
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 Table 2 b) Discrete Time Survival model for time to WHO stage 3 or 4 event 
 
Factor Level Adjusted Odds Ratio (95% c.i.) P-value 
Study SIte Entebbe 
Masaka 
1 (Reference) 
0.30 (0.16 ; 0.57) 
<0.001 
Sex Male 
Female 
0 (Reference) 
1.17 (0.56 ; 2.47) 
0.68 
Age Per 10 year increase 1.16 (0.85 ; 1.58) 0.35 
Visit Visit 2 (Month 6) 
Visit 3 (Month 12) 
1(Reference) 
1.40 (0.78 ; 2.51) 
0.26 
Baseline CD4 count Per 100 cell / µl increase 1.004 (0.89 ; 1.13) 0.95 
MDD (lagged) No 
Yes 
1 (Reference) 
0.52 (0.12 ; 2.20) 
0.12 
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Table 2 c) Logistic Regression model with robust variance for missing ART  
Factor Level Adjusted Odds Ratio (robust 95% c.i.) P-value 
Study SIte Entebbe 
Masaka 
1 (Reference) 
0.36 (0.17 ; 0.76) 
0.007 
Sex Male 
Female 
0 (Reference) 
0.83 (0.47 ; 1.47) 
0.52 
Age Per 10 year increase 0.98 (0.72 ; 1.33) 0.90 
Visit Visit 2 (Month 6) 
Visit 3 (Month 12) 
1(Reference) 
0.79 (0.48 ; 1.32) 
0.38 
Baseline CD4 count Per 100 cell / µl increase 0.94 (0.79 ; 1.11) 0.45 
MDD (lagged) No 
Yes 
1 (Reference) 
4.75 (1.87 ; 12.04) 
0.001 
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 Table 2 d) Discrete Time Survival model for time to visit to health facility  
Factor Level Adjusted Odds Ratio (95% c.i.) P-value 
Study SIte Entebbe 
Masaka 
1 (Reference) 
3.23 (2.33 ; 4.49) 
<0.001 
Sex Male 
Female 
0 (Reference) 
1.26 (0.86 ; 1.85) 
0.23 
Age Per 10 year increase 1.02 (0.86 ; 1.20) 0.82 
Visit Visit 2 (Month 6) 
Visit 3 (Month 12) 
1(Reference) 
0.68 (0.49 ; 0.93) 
0.015 
Baseline CD4 count Per 100 cell / µl increase 0.97 (0.91 ; 1.02) 0.23 
MDD (lagged) No 
Yes 
1 (Reference) 
1.71 (1.07 ; 2.73) 
0.024 
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Table 2 e) Discrete Time Survival model for time to first risky sexual behaviour 
 
Factor Level Adjusted Odds Ratio (95% c.i.) P-value 
Study SIte Entebbe 
Masaka 
1 (Reference) 
0.81 (0.56 ; 1.16) 
0.25 
Sex Male 
Female 
0 (Reference) 
0.55 (0.37 ; 0.81) 
0.003 
Age Per 10 year increase 0.71 (0.57 ; 0.88) 0.002 
Visit Visit 2 (Month 6) 
Visit 3 (Month 12) 
1(Reference) 
1.09 (0.76 ; 1.55) 
0.64 
Baseline CD4 count Per 100 cell / µl increase 0.98 (0.92 ; 1.05) 0.61 
MDD (lagged) No 
Yes 
1 (Reference) 
2.11 (1.2 7; 3.49) 
0.004 
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